Topic index / Shandong Beida Gaoke Huatai Pharmaceutical / Full chronicle

Shandong Beida Gaoke Huatai Pharmaceutical · Full chronicle and history

2026-06-09

National Drug Procurement Office Reports Serious Defects in Production Line of Centrally Procured Drug Amiodarone Hydrochloride Injection; Production Suspended

On June 9, 2026, the National Organization for Joint Drug Procurement announced that the production line for amiodarone hydrochloride injection, a centrally procured life-saving drug produced by Shandong Beida Gaokua Huatai Pharmaceutical, has serious defects and has been ordered to suspend production.

Location: Shandong · Importance III · Verification: Official claim · View causal chain →

2026-05-10

Shandong Drug Administration Finds Serious Defects at Huatai Pharmaceutical's Lyophilized Powder Injection Line, Suspends Production of Amiodarone Hydrochloride Injection

From May 10 to 15, 2026, the Shandong Provincial Drug Administration inspected Line 103 of the lyophilized powder injection workshop at Shandong Huatai Pharmaceutical, concluded that there was 1 serious defect and that the results were non-compliant, and decided to suspend production of amiodarone hydrochloride injection.

Location: Shandong · Importance III · Verification: Official claim · View causal chain →